Mycoplasma Contamination

Mycoplasma are a genus of small, simple bacteria that lack a cell wall, making them resistant to many common antibiotics and difficult to detect by standard microbiological methods. In the context of biomanufacturing, Mycoplasma are considered critical adventitious agents. Contamination of cell cultures or raw materials poses a severe risk to product quality and patient safety. Mycoplasma can significantly alter the physiology of production cells, affecting growth rates, protein expression, and post-translational modifications, thereby compromising product efficacy and consistency. Furthermore, their presence signifies a major breach in aseptic processing and manufacturing control. Regulatory agencies worldwide mandate rigorous testing for Mycoplasma at critical stages, including cell bank qualification and unprocessed bulk harvest, to ensure products are free from this contamination.

• Time: The 28-day incubation period for the compendial culture method creates significant delays in lot release and process development.
• Viable but Non-culturable (VBNC) State: Some Mycoplasma species may not grow in standard culture media but can still be present and viable, leading to false-negative results with the culture method.
• Validation of NAT/PCR: Rapid PCR-based methods must undergo extensive validation to demonstrate high sensitivity (limit of detection), specificity (no cross-reaction with other bacteria), and robustness, proving their suitability as replacements for compendial methods.
• Inhibition: Test articles, particularly complex biological matrices, can contain substances that inhibit PCR reactions, requiring robust sample preparation and the use of internal controls.

The expectation for Mycoplasma control is consistent across all phases of development: the product must be free from contamination.

• Pre-clinical / Phase 1: Cell banks (Master and Working) must be demonstrated to be free of Mycoplasma. A qualified assay is used to test the unprocessed bulk harvest.
• Phase 2 / 3: Validation of NAT/PCR methods should follow ICH Q2(R2) principles where applicable, supplemented with compendial expectations (USP <63>, EP 2.6.7) for sensitivity, specificity, and suitability as a replacement for culture.
• Commercial (BLA/MAA): Routine testing of each unprocessed bulk lot using a fully validated method is a standard requirement for product release. Any confirmed positive result typically leads to batch rejection and a thorough manufacturing investigation.

Mycoplasma contamination presents a critical risk to manufacturing operations and product quality.

• Safety Risk (High): Presence indicates a severe failure of aseptic manufacturing controls. This loss of control implies a risk of other, potentially pathogenic, contaminants being present. Furthermore, Mycoplasma can degrade the product or produce metabolites that could pose a safety risk.
• Efficacy Risk (High): Mycoplasma can dramatically impact the health of production cell cultures. They compete for essential nutrients (like arginine), alter gene expression, cause chromosomal aberrations, and modify protein synthesis. This can lead to significantly reduced product yield, incorrect post-translational modifications, and a loss of biological activity (potency).

• Purity & Impurities: Mycoplasma is a gross contaminant. Its presence means the product is fundamentally impure and adulterated.
• Potency/Biological Activity: Directly and negatively impacted. Contamination often leads to a significant decrease in product potency.
• Bioburden/Sterility: A positive Mycoplasma result is a critical failure of the overall sterility assurance and aseptic control program.

There is a strong industry and regulatory push toward rapid NAT/PCR-based methods to replace the 28-day culture test, enabling faster lot release and more responsive process control. Key mitigation strategies include:

• Rigorous screening of all raw materials of biological origin.
• Robust aseptic techniques and environmental monitoring.
• Use of 0.1 µm filters for high-risk fluid streams. This reduces risk but must be combined with comprehensive raw material control and aseptic practices, as it is not considered a sterilizing step for Mycoplasma.

Regulatory requirements for Mycoplasma testing are well-established and harmonized globally.

• 21 CFR 610.30 (Test for Mycoplasma): The US FDA regulation mandating that biological products be tested and shown to be free of Mycoplasma.
• European Pharmacopoeia (EP) Chapter 2.6.7: Details the compendial culture and indicator cell methods and provides requirements for validating NAT-based alternatives.
• USP General Chapter <63>: The United States Pharmacopeia chapter provides guidance on Mycoplasma testing, closely aligning with the EP.
• ICH Q5A(R2): This guideline on the viral safety of biotechnology products also addresses the control of adventitious agents like Mycoplasma in cell banks and biological raw materials.
• ICH Q5D (cell substrates) and WHO guidelines also stress the importance of Mycoplasma control in cell banks and biological manufacturing.